TP53 and non-small cell lung carcinoma: Another study exploiting dynamic ctDNA analysis to monitor genetic evolutions during ensartinib treatment in NSCLC showed that TP53 mutations promoted tumor evolution and accelerated occurrence of resistance, thus indicating TP53 mutations at baseline were independently correlated with worse clinical outcomes [87].